Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Latest news

8/27/2019 Ranking of Russian Pharmaceutical Distributors (Q1 – Q2)

It is unlikely that by the end of this year the pharmaceutical wholesale will have seen any significant achievements or failures. As of yet, the market is only developing in terms of public procurement. The public procurement segment has always been a very specific area, with a limited circle of players and its own rules, which are also very vaguely worded. For example, that massive breakdown in trading due to difficulties in setting the initial maximum price of the contract.

8/20/2019 Database Update: Pharmaceutical Drug Import for Clinical Trials to Russia (June 2019)

Between January and June 2019, Russia imported 319.8 thousand units, 8.2 bln RUB worth of pharmaceuticals for clinical trials (CT) (free circulation prices), which is in physical terms (units) 15.8% lower and in monetary terms (rubles) 1.4% lower than that of the same period in 2018. While the negative dynamics in physical terms have been registered at least thrice since 2013, the negative dynamics in monetary terms have been registered for the first time.

8/16/2019 Ranking of Russian Pharmacy Chains (Q1 – Q2 2019)

By June 2019, the pharmaceutical drug inflation rates have reached a value of 6%, especially against the background of the results of the previous two years. The rising prices, given the decreasing incomes of the population, will obviously be unable to lead to higher demand, and, as a result, the dynamics of the retail and commercial market for the first half of 2019, after a short surge in the first quarter, returned to last year's values, which are closer to stagnation than to growth (+2.4%).

8/15/2019 Database Update: API Import to Russia (June 2019)

Between January and June 2019, Russia imported 56.4 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms (rubles) 21% higher than that of the same period in 2018. In physical terms, Russia imported 5.8 thousand tons of APIs, and the dynamics are +6.1%, if calculated in kilos. 96.6% of the API import accounts for pharmacopoeial APIs.

8/9/2019 Database Update: Import of Veterinary Drugs, Feed Supplements, and Veterinary APIs to Russia (June 2019)

Between January and June 2019, Russia imported 31.9 bln RUB worth of veterinary products (free circulation prices), which is in monetary terms (rubles) only 0.1% higher than that of the same period in 2018. The dynamics are due to a decrease of the import of feed supplements in monetary terms, -8.2%. However, the import of feed supplements still amounts to as much as 16.8 bln RUB. The dynamics of the import of veterinary drugs in monetary terms are +10.4%, with over 13.8 bln RUB. The dynamics of the import of veterinary APIs are as high as +22%, with nearly 1.3 bln RUB.

All news [99]

Our competences

RNC Pharma is focused on providing information about development trends of Russian pharmaceutical market infrastructure component. Our experts also provide services on strategic marketing, such as forecasting, business planning, etc.